Alveolar Type II Cells Possess the Capability of Initiating Lung Tumor Development

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Lin, Chuwen ^a   Song, Hai ^a   Huang, Cecilia ^a   Yao, Erica ^a   Gacayan, Rhodora ^a   Xu, Shan Mei ^a   Chuang, Pao Tien ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; PROTEIN P53; SURFACTANT PROTEIN C; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CELL PROLIFERATION; CELL TYPE; GENE ACTIVATION; GENE ACTIVITY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; LUNG ALVEOLUS CELL TYPE 2; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOUSE; MOUSE STRAIN; NONHUMAN; ONCOGENE K RAS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; GENES, P53; GENES, RAS; HUMANS; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; MUTATION; NEOPLASTIC STEM CELLS; PULMONARY ALVEOLI;

EID: 84871454926     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053817     Document Type: Article

References (47)

1. McErlean A, Ginsberg MS, (2011) Epidemiology of lung cancer. Semin Roentgenol 46: 173-177.
2. Ramalingam SS, Owonikoko TK, Khuri FR, (2011) Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin 61: 91-112.
3. Murala S, Alli V, Kreisel D, Gelman AE, Krupnick AS, (2010) Current status of immunotherapy for the treatment of lung cancer. J Thorac Dis 2: 237-244.
4. Vallieres E, Peters S, Van Houtte P, Dalal P, Lim E (2011) Therapeutic advances in non-small cell lung cancer. Thorax.
5. Reungwetwattana T, Weroha SJ, Molina JR (2011) Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non-Small-Cell Lung Cancer (NSCLC). Clin Lung Cancer.
6. Cheng L, Alexander RE, Maclennan GT, Cummings OW, Montironi R, et al. (2012) Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol.
7. Greulich H, (2010) The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes Cancer 1: 1200-1210.
8. Gazdar AF, Girard L, Lockwood WW, Lam WL, Minna JD, (2010) Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst 102: 1310-1321.
9. Vahakangas KH, Bennett WP, Castren K, Welsh JA, Khan MA, et al. (2001) p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res 61: 4350-4356.
10. Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, et al. (2004) Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 64: 2307-2316.
11. Kwak I, Tsai SY, DeMayo FJ, (2004) Genetically engineered mouse models for lung cancer. Annu Rev Physiol 66: 647-663.
12. Frese KK, Tuveson DA, (2007) Maximizing mouse cancer models. Nat Rev Cancer 7: 645-658.
13. de Seranno S, Meuwissen R, (2010) Progress and applications of mouse models for human lung cancer. Eur Respir J 35: 426-443.
14. Politi K, Pao W, (2011) How genetically engineered mouse tumor models provide insights into human cancers. J Clin Oncol 29: 2273-2281.
15. Meuwissen R, Berns A, (2005) Mouse models for human lung cancer. Genes Dev 19: 643-664.
16. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, et al. (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243-3248.
17. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, et al. (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29: 418-425.
18. Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, et al. (2011) Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473: 101-104.
19. Kadara H, Kabbout M, Wistuba II, (2012) Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology 17: 50-65.
20. DuPage M, Dooley AL, Jacks T (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4: 1064-1072. PMCID: PMC2757265.
21. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
22. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
23. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, et al. (2006) Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20: 1496-1510.
24. Regales L, Balak MN, Gong Y, Politi K, Sawai A, et al. (2007) Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One 2: e810.
25. Morrisey EE, Hogan BL, (2010) Preparing for the first breath: genetic and cellular mechanisms in lung development. Dev Cell 18: 8-23.
26. Sutherland KD, Berns A, (2010) Cell of origin of lung cancer. Mol Oncol 4: 397-403.
27. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, et al. (2005) Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121: 823-835.
28. Rawlins EL, Okubo T, Xue Y, Brass DM, Auten RL, et al. (2009) The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. Cell Stem Cell 4: 525-534.
29. Joyner AL (2000) Gene targeting: a practical approach, second edition (Oxford University Press).
30. Andreeva AV, Kutuzov MA, Voyno-Yasenetskaya TA, (2007) Regulation of surfactant secretion in alveolar type II cells. Am J Physiol Lung Cell Mol Physiol 293: L259-271.
31. Danielian PS, Muccino D, Rowitch DH, Michael SK, McMahon AP, (1998) Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase. Curr Biol 8: 1323-1326.
32. Soriano P, (1999) Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 21: 70-71.
33. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L, (2007) A global double-fluorescent Cre reporter mouse. Genesis 45: 593-605.
34. Branda CS, Dymecki SM, (2004) Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev Cell 6: 7-28.
35. Nagy A, Gertsenstein M, Vintersten K, Behringer R (2003) Manipulating the Mouse Embryo: A Laboratory Manual, Third Edition (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press).
36. Pao W, Chmielecki J, (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10: 760-774.
37. da Cunha Santos G, Shepherd FA, Tsao MS, (2011) EGFR mutations and lung cancer. Annu Rev Pathol 6: 49-69.
38. Eliasz S, Liang S, Chen Y, De Marco MA, Machek O, et al. (2010) Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene 29: 2488-2498.
39. Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, et al. (2011) The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest 121: 1373-1385.
40. Xu X, Rock JR, Lu Y, Futtner C, Schwab B, et al. (2012) Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. Proc Natl Acad Sci U S A 109: 4910-4915.
41. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, et al. (2005) The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65: 10280-10288.
42. Chapman HA, Li X, Alexander JP, Brumwell A, Lorizio W, et al. (2011) Integrin alpha6beta4 identifies an adult distal lung epithelial population with regenerative potential in mice. J Clin Invest 121: 2855-2862.
43. Kitamura H, Kameda Y, Ito T, Hayashi H, Nakamura N, et al. (1997) Cytodifferentiation of atypical adenomatous hyperplasia and bronchioloalveolar lung carcinoma: immunohistochemical and ultrastructural studies. Virchows Arch 431: 415-424.
44. Pao W, Girard N, (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12: 175-180.
45. Rodriguez CI, Buchholz F, Galloway J, Sequerra R, Kasper J, et al. (2000) High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat Genet 25: 139-140.
46. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG, (2005) Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 33: e36.
47. Glasser SW, Burhans MS, Korfhagen TR, Na CL, Sly PD, et al. (2001) Altered stability of pulmonary surfactant in SP-C-deficient mice. Proc Natl Acad Sci U S A 98: 6366-6371.